Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eight-Treg Study in Living Donor Kidney Transplant Recipients
NCT06777719Phase 1Recruiting
- Sponsor
- CHU de Nantes
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Eight Treg in kidney transplantation, sponsored by CHU de Nantes. Primary endpoints: Treatment-related adverse events at 3 months and Dose-limiting toxicity at 3 months. Started Mar 2025; status: recruiting.
02
Drugs
Eight Treg
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT06777719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777719.